Alexion receives approval for two enzyme replacement products in Europe

The European Commission has approved two enzyme replacement therapies, Kanuma (sebelipase alfa) and Strensiq (asfotase alfa), from Alexion (Nasdaq: ALXN).

Kanuma has been approved for long-term enzyme replacement therapy in patients of all ages with lysosomal acid lipase deficiency (LAL-D). It is the first approved treatment in the European Union for patients with LAL-D, an ultra-rare genetic metabolic disease in which patients suffer multi-organ damage and premature death.

Strensiq has been approved for long-term enzyme replacement therapy in patients with pediatric-onset hypophosphatasia to treat the bone manifestations of the disease. This condition is associated with multiple bone manifestations including rickets, altered calcium and phosphate metabolism and respiratory compromise that may require ventilation. Strensiq is the first therapy approved in the European Union to treat hypophosphatasia.